Evaluating the Safety and Efficacy of Concizumab in Hemophilia A/B Patients: A Systematic Review
Open Access
- 14 May 2025
- journal article
- review article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 31
Abstract
Background: Hemophilia A and B are X-linked recessive bleeding disorders caused by deficiencies of coagulation factors VIII and IX, respectively. These conditions lead to spontaneous bleeding, joint damage, inhibitor development, and the burden of frequent intravenous infusions. Concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), is a novel non-factor therapy that enhances thrombin generation. This systematic review evaluates the efficacy and safety of concizumab prophylaxis in patients with hemophilia A and B. Methods: This systematic review was conducted in accordance with PRISMA guidelines. Randomized controlled trials (RCTs) assessing the use of concizumab in hemophilia A or B were identified through a comprehensive search of electronic databases. Outcomes of interest included annualized bleeding rate (ABR), thrombin generation, bleeding episodes, immunogenicity, and adverse events. The Cochrane Risk of Bias Tool 2.0 was used for quality assessment. Results: Five studies were included. Concizumab prophylaxis was associated with a notable reduction in ABR, with reported decreases from 9.4 to 1.3 episodes/year and from 19.6 to 2.9 episodes/year in hemophilia A, and from 14.9 to 1.6 episodes/year in hemophilia B. Thrombin generation increased in a dose-dependent manner and stabilized by week 24. Across all studies, bleeding episodes were significantly reduced. Adverse events were primarily mild to moderate. No thromboembolic events were reported. Conclusion: Concizumab appears to be an effective and safe prophylactic treatment for patients with hemophilia A and B, demonstrating consistent reductions in bleeding rates and enhanced thrombin generation. Further long-term studies are warranted to establish its sustained safety and efficacy.Keywords
This publication has 31 references indexed in Scilit:
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017
- Inhibitor development in haemophiliaHaemophilia, 2016
- Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia ANew England Journal of Medicine, 2016
- Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trialJournal of Thrombosis and Haemostasis, 2015
- The modern treatment of haemophilia: a narrative review2013
- Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical managementBritish Journal of Haematology, 2011
- Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesTherapeutic Advances in Drug Safety, 2011
- Treatment of hemophilia: a review of current advances and ongoing issuesJournal of Blood Medicine, 2010
- Recent Improvements in the Clinical Treatment of Coagulation Factor InhibitorsSeminars in Thrombosis and Hemostasis, 2009
- Therapy for haemophilia: recent advances and goals for the futureExpert Opinion on Emerging Drugs, 2005